Analyst firms · Morgan Stanley · DNLI
Morgan Stanley DNLI price target and rating history
Denali Therapeutics Inc. (DNLI) · Health Care
Morgan Stanley rates Denali Therapeutics Inc. (DNLI) Overweight with a $33 price target, as of its latest action on Mar 7, 2025. It has published 3 rating actions on DNLI since August 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a DNLI price target in the last 12 months, the median target is $35.
- Current rating
- Overweight
- Price target
- $33
- Median target, all firms
- $35
- Actions on DNLI
- 3
Morgan Stanley price target on DNLI
Every Morgan Stanley rating on DNLI
- Mar 7, 2025
- Jan 6, 2022
- Aug 16, 2021
How other firms rate DNLI
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Overweight | $35 | Nov 13, 2026 |
| H.C. Wainwright | Buy | $42 | Mar 26, 2026 |
| Wolfe Research | Peer Perform | Feb 24, 2026 | |
| UBS | Buy | $25 | Jan 7, 2026 |
Questions about Morgan Stanley and DNLI
- What is Morgan Stanley's price target for DNLI?
- Morgan Stanley's latest stated price target for Denali Therapeutics Inc. (DNLI) is $33, from its action on Mar 7, 2025.
- What is Morgan Stanley's rating on DNLI?
- Morgan Stanley rates DNLI Overweight, a bullish rating, as of Mar 7, 2025.
- When did Morgan Stanley last change its view on DNLI?
- On Mar 7, 2025, Morgan Stanley resumes coverage at Overweight, price target $41 to $33.
- How does Morgan Stanley's DNLI target compare with other analysts?
- Across 3 firms with a DNLI price target in the last 12 months, the median target is $35.
More DNLI rating histories
All Morgan Stanley ratingsDNLI news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.